Advertisement

Pediatric Nephrology

, Volume 8, Issue 2, pp 157–163 | Cite as

Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture

  • Matthias Mohrmann
  • Stefan Ansorge
  • Uwe Schmich
  • Barbara Schönfeld
  • Matthias Brandis
Original Article

Abstract

Ifosfamide (IF) and cyclophosphamide (CP) are highly effective alkylating cytostatic drugs. IF and CP have to be activated through a metabolic step in vivo; numerous metabolites are known. While both IF and its structural isomer CP have severe urotoxic side effects, only IF is also a nephrotoxic drug, causing tubular damage resulting in Fanconi syndrome in some cases. Little information is available regarding the pathogenic mechanism of tubular damage by IF. We used the renal epithelial cell line LLC-PK1, which has many properties of the proximal tubule, in order to investigate the toxicity of IF and CP and of their reactive metabolites 4-hydroxy-IF (4-OH-IF), 4-hydroxy-CP (4-OH-CP), acrolein and chloracetaldehyde (CAA). Protein content of monolayers, DNA and RNA synthesis were determined by standard techniques (thymidine and uridine incorporation). IF and CP had the lowest toxicities of all compounds tested. Both drugs inhibited thymidine incorporation by about 30% at a concentration of 300 μmol/l after 1 h incubation. 4-OH-IF and 4-OH-CP were significantly more toxic than the parent drugs. Thymidine incorporation, the most sensitive parameter, was reduced by about 70% by 300 μmol/l of either compound. In addition, 4-OH-CP reduced the total protein content of monolayers. 4-OH-IF did not effect protein content and RNA synthesis. Acrolein, the most toxic metabolite tested, reduced all three parameters significantly at concentrations of 50–75 μmol/l after 1 h. Incubation of cells with 100 μmol/l of acrolein showed an effect after only 1 min. CAA significantly damaged monolayers with a reduction of total protein at a concentration of 50–100 μmol/l. Thymidine incorporation was decreased only moderately by CAA, while uridine incorporation was stimulated, which may be interpreted to reflect a mechanism of repair. We conclude that both CP and IF and their metabolites are toxic in renal tubular cells in culture. CAA may play a larger role in the development of renal tubular damage after therapy with IF than was previously recognized.

Key words

Ifosfamide Cyclophosphamide Nephrotoxicity Fanconi syndrome Chloracetaldehyde 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brock N (1989) Oxazaphosphorine cytostatics: past — present — future. Cancer Res 49: 1–7Google Scholar
  2. 2.
    Arnold H, Bourseaux F, Brock N (1958) Chemotherapeutic action of a cyclic nitrogen mustard phosphamide ester (B 518-Asta). Nature 181: 931Google Scholar
  3. 3.
    Dechant KL, Brogden RN, Pilkington T, Faulds D (1991) Ifosfamide/Mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42: 428–467Google Scholar
  4. 4.
    Bielicki L, Voelcker G, Hohorst HJ (1984) Activated cyclophosphamide: an enzyme mechanism-based suicide inactivator of DNA polymerase/3′–5′ exonuclease. J Cancer Res Clin Oncol 107: 195–918Google Scholar
  5. 5.
    Hohorst HJ, Bielicki L, Voeleker G (1986) The enzymatic basis of cyclophosphamide specificity. Adv Enzyme Regul 25: 99–122Google Scholar
  6. 6.
    Clarke L, Waxman DJ (1989) Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. Cancer Res 49: 2344–2350Google Scholar
  7. 7.
    Low JE, Borch RF, Sladek NE (1983) Further studies on the conversion of 4-hydroxyoxazaphosphorines to reactive mustards and acrolein in inorganic buffers. Cancer Res 43: 5815–5820Google Scholar
  8. 8.
    Norpoth K, Müller G, Raidt H (1976) Isolierung und Charakterisierung zweier Hauptmetabolite von Ifosfamid aus Patientenurin. Arzneimittelforschung 26: 1376–1377Google Scholar
  9. 9.
    Brade WP, Herdrich K, Varini M (1985) Ifosfamide — pharmacology, safety and therapeutic potential. Cancer Treat Rev 12: 1–47Google Scholar
  10. 10.
    Jürgens H, Exner U, Kühl J, Ritter J, Treuner J (1989) High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma. Cancer Chemother Pharmacol 24: 40–44Google Scholar
  11. 11.
    Magrath I, Sandlund J, Raynor A, Rosenberg S, Arasi V (1986) A phase II study of ifosfamide in the treatment of recurrent sarcomas in young people. Cancer Chemother Pharmacol 18: 25–28Google Scholar
  12. 12.
    Pinkerton CR, Pritchard J (1989) A phase II study of ifosfamide in pediatric solid tumors. Cancer Chemother Pharmacol 24: 13–15Google Scholar
  13. 13.
    Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G (1979) Acrolein, the causative factor of urotoxic side effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Drug Res 29: 659–661Google Scholar
  14. 14.
    Holoye PY, Glisson BS, Lee JS, Dhingra HM, Murphy WK (1990) Ifosfamide with mesna uroprotection in the management of lung cancer. Am J Clin Oncol 13: 148–155Google Scholar
  15. 15.
    Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G (1986) Prediction of ifosfamide/Mesna associated encephalopathy. Eur J Cancer Clin Oncol 22: 815–819Google Scholar
  16. 16.
    Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK (1990) Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol 8: 1399–1401Google Scholar
  17. 17.
    Shaw IC, Graham MI (1987) Mesna — a short review. Cancer Treat Rev 14: 67–86Google Scholar
  18. 18.
    Burk CD, Restaino I, Kaplan BS, Meadows AT (1990) Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. J Pediatr 117: 331–335Google Scholar
  19. 19.
    Goren MP, Wright RK, Horowitz ME, Pratt CB (1987) Ifosfamide-induced subclinical tubular nephrotoxicity despite mesna. Cancer Treat Rep 71: 127–130Google Scholar
  20. 20.
    Skinner R, Pearson ADJ, Price L, Cunningham K, Craft AW (1989) Hypophosphataemic rickets after ifosfamide treatment in children. BMJ 298: 1560–1561Google Scholar
  21. 21.
    Skinner R, Pearson ADJ, Price L, Coulthard MG, Craft AW (1990) Nephrotoxicity after ifosfamide. Arch Dis Child 65: 732–738Google Scholar
  22. 22.
    Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F (1991) Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an international society of pediatric oncology report. J Clin Oncol 9: 2177–2182Google Scholar
  23. 23.
    Mohrmann M, Pauli A, Ritzer M, Schönfeld B, Seifert B, Brandis M (1992) Inhibition of sodium-dependent transport systems in LLC-PK1 cells by metabolites of ifosfamide. Renal Physiol Biochem 15: 289–301Google Scholar
  24. 24.
    Mohrmann M, Pauli A, Schönfeld B, Walkenhorst H, Brandis M (1993) Effect of ifosfamide metabolites on sodium dependent phosphate transport in a model of proximal tubular cells (LLC-PK1) in culture. Renal Physiol Biochem 16: 285–298Google Scholar
  25. 25.
    Hull RN, Cherry WR, Weaver GW (1976) The origin and characteristics of a pig kidney cell strain, LLC-PK1. In Vitro 12: 670–677Google Scholar
  26. 26.
    Biber J, Brown CDA, Murer H (1983) Sodium-dependent transport of phosphate in LLC-PK1 cells. Biochim Biophys Acta 735: 325–330Google Scholar
  27. 27.
    Rabito CA, Karish MV (1983) Polarized amino acid transport by an epithelial cell line of renal origin (LLC-PK1). The apical systems. J Biol Chem 258: 2543–2547Google Scholar
  28. 28.
    Rabito CA, Karish MV (1982) Polarized amino acid transport by an epithelial cell line of renal origin (LLC-PK1). The basolateral systems. J Biol Chem 257: 6802–6808Google Scholar
  29. 29.
    Amsler K, Cook JS (1982) Development of Na+-dependent hexose transport in a cultured line of porcine kidney cells. Am J Physiol 242 (Cell Physiol 11): C94-C101Google Scholar
  30. 30.
    Mullin JM, McGinn MT, Snock KV, Kofeldt LM (1989) Na+-independent sugartransport by cultured renal (LLC-PK1) epithelial cells. Am J Physiol 257 (Renal Fluid Electrolyte Physiol 26): F11-F17Google Scholar
  31. 31.
    Cantiello HF, Scott JA, Rabito CA (1986) Polarized distribution of the Na/H exchangesystem in a renal cell line (LLC-PK1) with characteristics of proximal tubular cells. J Biol Chem 261: 3252–3258Google Scholar
  32. 32.
    Mohrmann M, Cantiello HF, Ausiello DA (1987) Renal epithelial cell growth can occur in absence of Na+−H+ exchanger activity. Am J Physiol 253: C633-C638Google Scholar
  33. 33.
    Mohrmann I, Mohrmann M, Biber J, Murer H (1986) Sodium-dependent transport of Pi by an established intestinal epithelial cell line (CaCo-2). Am J Physiol 250: G323-G330Google Scholar
  34. 34.
    Mohrmann I, Mohrmann M, Biber J, Murer H (1986) Stimulation of Na/phosphate cotransport in LLC-PK1 cells by 12-O-tetradecanoylphorbol 13-acetate (TPA). Biochim Biophys Acta 860: 35–43Google Scholar
  35. 35.
    Moran A, Handler JS, Hagan M (1986) Role of cell replication in regulation of Na-coupled hexose transport in LLC-PK1 epithelial cells. Am J Physiol 250: C314-C318Google Scholar
  36. 36.
    Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76–85Google Scholar
  37. 37.
    Pearcey R, Calvert R, Mehta A (1988) Disposition of ifosfamide in patients receiving ifosfamide infusion therapy for the treatment of cervical carcinoma. Cancer Chemother Pharmacol 22: 353–355Google Scholar
  38. 38.
    Low JE, Borch RF, Sladek NE (1982) Conversion of 4-hydroperoxycyclophosphamide and 4-hydroxycyclophosphamide to phosphoramide mustard and acrolein mediated by bifunctional catalysts. Cancer Res 42: 830–837Google Scholar
  39. 39.
    Wagner T, Heydrich D, Jork T, Voelcker G, Hohorst HJ (1981) Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. J Cancer Res Clin Oncol 100: 95–104Google Scholar
  40. 40.
    Pohl J, Stekar J, Hilgard P (1989) Chloroacetaldehyde and its contribution to urotoxicity during treatment with cyclophosphamide or ifosfamide. Drug Res 39: 704–705Google Scholar
  41. 41.
    Goren MP, Wright RK, Pratt CB, Pell FE (1986) Dechlorethylation of ifosfamide and neurotoxicity. Lancet II: 1219–1220Google Scholar
  42. 42.
    Winckler K, Obe G, Madle S, Kocher-Becker U, Kocher W, Nau H (1987) Cyclophosphamide: interstrain differences in the production of mutagenic metabolites by S9-fractions from liver and kidney in different mutagenicity test systems in vitro and in the teratogenic response in vivo between CBA and C57 BL mice. Teratogenesis Carcinog Mutagen 7: 399–409Google Scholar
  43. 43.
    Brock N, Hilgard P, Peukert M, Pohl J, Sindermann H (1988) Basis and new developments in the field of oxazaphosphorines. Cancer Invest 6: 513–532Google Scholar
  44. 44.
    Ohno Y, Ormstad K, Ross D, Orrenius S (1985) Mechanism of allyl alcohol toxicity and protective effects of low molecular weight thiols studied with isolated rat hepatocytes. Toxicol Appl Pharmacol 78: 169–179Google Scholar
  45. 45.
    Grafstrom RC, Dypbukt JM, Willey JC, Sundqvist K, Edman C, Atzori L, Harris CC (1988) Pathobiological effects of acrolein in cultured human bronchial epithelial cells. Cancer Res 48: 1717–1721Google Scholar
  46. 46.
    Kimes BW, Morris DR (1971) Inhibition of nucleic acid and protein synthesis inE. coli by oxidized polyamines and acrolein. Biochim Biophys Acta 228: 235–244Google Scholar
  47. 47.
    Marano F, Puiseux-Dao S (1982) Acrolein and cell cycle. Toxicol Lett 14: 143–149Google Scholar
  48. 48.
    Marano F, Demestere M (1976) Ultrastructural autoradiographic study of the intracellular fixation of3H acrolein. Experientia 32: 501–502Google Scholar
  49. 49.
    Sarosy G (1989) Ifosfamide — pharmacologic overview. Semin Oncol 16: 2–8Google Scholar

Copyright information

© IPNA 1994

Authors and Affiliations

  • Matthias Mohrmann
    • 1
  • Stefan Ansorge
    • 1
  • Uwe Schmich
    • 1
  • Barbara Schönfeld
    • 1
  • Matthias Brandis
    • 1
  1. 1.Department of PaediatricsAlbert-Ludwigs-Universität FreiburgGermany

Personalised recommendations